Form 4 RenovoRx, Inc. For: Oct 01 Filed by: Marton Laurence
RenovoRx, Inc. (RNXT)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
RNXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNXT alerts
High impacting RenovoRx, Inc. news events
Weekly update
A roundup of the hottest topics
RNXT
News
- We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully [Yahoo! Finance]Yahoo! Finance
- RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology PhysiciansGlobeNewswire
- RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic CancerGlobeNewswire
- RenovoRx, Inc. (NASDAQ: RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $8.25. They now have a "buy" rating on the stock.MarketBeat
- MyTomorrows partners with pancreatic cancer pressure group to drive trials [Yahoo! Finance]Yahoo! Finance
RNXT
Earnings
- 11/13/23 - Beat
RNXT
Analyst Actions
- 9/12/24 - Ascendiant Capital
RNXT
Sec Filings
- 10/2/24 - Form 4
- 10/2/24 - Form 4
- 10/2/24 - Form 4
- RNXT's page on the SEC website